Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

    ... orally, twice daily for 21-day cycles, in patients with Acute Myelogenous Leukemia (AML) orMyelodysplastic Syndrome (MDS). ...

    Clinical Trial last updated 04/27/2016 - 3:39pm.

  2. Myelodysplastic Syndromes (MDS)

    ... others are more severe, and carry a high risk of becoming acute myelogenous leukemia (AML). The subtype you have, and the severity of your ...

    Page last updated 02/27/2017 - 7:36am.

  3. Acute Myeloid Leukemia (AML)

    Acute Myeloid Leukemia (AML) ... fight off infection. AML is also known as acute myelogenous leukemia , acute myeloblastic leukemia and acute nonlymphocytic ...

    Topic section last updated 07/07/2016 - 3:15pm.

  4. Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

    ... risk AML (i.e. preceding MDS, myeloproliferative syndromes, leukemia due to cytotoxic chemotherapy for another condition, adverse ... or any subjects > 70 years of age with untreated AML. Acute promyelocytic leukemia (FAB M3) is excluded Please note: prior ...

    Clinical Trial last updated 06/03/2016 - 2:24pm.

  5. Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease (UF-BMT-MRD-101)

    For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02370888 ...

    Clinical Trial last updated 04/29/2016 - 2:38pm.

  6. Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

    For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT01289457 ...

    Clinical Trial last updated 04/29/2016 - 12:27pm.

  7. SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)

    For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02684162 ...

    Clinical Trial last updated 04/29/2016 - 12:20pm.

  8. Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

    For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02141477 ...

    Clinical Trial last updated 04/29/2016 - 11:19am.

  9. LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)

    For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02649764 ...

    Clinical Trial last updated 04/28/2016 - 1:47pm.

  10. Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

    For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02250937 ...

    Clinical Trial last updated 04/28/2016 - 3:41pm.